Company intelligence / Profile preview

LASARRUS

Ownership: Private
Development stage: Preclinical

Overview

LASARRUS has developed and deployed a wearable, multimodal sensor platform that enables early detection and remote monitoring of COPD. The technology provides comprehensive cardiopulmonary assessment to reduce hospital readmissions by enabling early symptom identification. Clinical studies have demonstrated the accuracy of their mobile phone-based auscultation for diagnosing chronic lung diseases[8].

Therapeutic areas: Pulmonology
Modalities: DeviceWearable sensor systemNon-pharmacological therapy (remote physiological monitoring)
Industry: Physiological Monitoring

Partnerships

Not explicitly listed; references to academic collaborations and industry recognition[5].

Beyond the preview

Go deeper on LASARRUS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LASARRUS.

Explore the full profile